Biorestorative Therapies (NASDAQ:BRTX) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Biorestorative Therapies (NASDAQ:BRTX) announced its quarterly earnings data on Wednesday. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.08, FiscalAI reports. Biorestorative Therapies had a negative net margin of 3,956.11% and a negative return on equity of 430.91%. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.31 million.

Biorestorative Therapies Price Performance

Shares of BRTX stock traded up $0.01 during trading hours on Friday, reaching $0.20. 303,389 shares of the stock were exchanged, compared to its average volume of 6,588,556. Biorestorative Therapies has a 12-month low of $0.17 and a 12-month high of $2.05. The business’s fifty day moving average is $0.25 and its two-hundred day moving average is $0.76. The firm has a market capitalization of $4.97 million, a P/E ratio of -0.12 and a beta of 0.29.

Hedge Funds Weigh In On Biorestorative Therapies

Several large investors have recently bought and sold shares of the business. Citadel Advisors LLC acquired a new position in shares of Biorestorative Therapies during the 3rd quarter worth about $152,000. DRW Securities LLC acquired a new stake in shares of Biorestorative Therapies during the 4th quarter worth about $55,000. Finally, Virtu Financial LLC raised its position in shares of Biorestorative Therapies by 102.4% during the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after acquiring an additional 12,319 shares in the last quarter. Hedge funds and other institutional investors own 69.38% of the company’s stock.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.